Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IXQUF (IXQUF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: IXQUF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.09% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 |
52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84650568 | Price to Sales(TTM) - |
Enterprise Value 84650568 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1610376 |
Shares Outstanding - | Shares Floating 1610376 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
IXQUF
Company Overview
History and Background
Ixico PLC, (IXQUF) was founded in 2006 and provides advanced neuroscience imaging to help pharmaceutical companies accelerate the development of new medicines for neurological diseases. They are headquartered in London, UK.
Core Business Areas
- Neuroimaging Services: Provides services related to capturing, analyzing, and interpreting neuroimaging data, predominantly MRI, to support clinical trials for neurological disorders.
- Data Analytics and Insights: Offers data analytics and insights derived from neuroimaging data, helping pharmaceutical companies understand disease progression and treatment response.
- Technology Platform: ixCONNECTu00ae is Ixicou2019s secure cloud-based platform which is utilized to ensure high quality data from collection to analysis.
Leadership and Structure
IXICO is led by a management team with expertise in neuroimaging, drug development, and technology. The company has a board of directors that provides oversight and guidance.
Top Products and Market Share
Key Offerings
- Clinical Trial Imaging Services: Neuroimaging services for Phase I-III clinical trials, focusing on neurological diseases like Alzheimer's, Parkinson's, and Huntington's. Market share data not readily available. Competitors include Bioclinica, Bio-Imaging Technologies (now Clario), and Medpace Reference Laboratories.
- Imaging Biomarkers: Development and application of imaging biomarkers to assess drug efficacy and disease progression. Market share data not readily available. Competitors include various academic research institutions and specialized imaging CROs.
- ixCONNECTu00ae: Ixicou2019s secure cloud-based platform which is utilized to ensure high quality data from collection to analysis. Market share data not readily available. Competitors include Signant Health, Clario and ERT.
Market Dynamics
Industry Overview
The neuroimaging services market is growing due to increasing R&D spending in neurological disease drug development, rising prevalence of neurological disorders, and the need for objective biomarkers in clinical trials.
Positioning
IXICO positions itself as a specialist provider of high-quality neuroimaging services and data analytics, focusing on complex neurological disorders. They hold a competitive advantage with a focus on neurology and advanced imaging techniques and the ixCONNECTu00ae platform.
Total Addressable Market (TAM)
The global neuroimaging market is projected to reach billions of USD, with the clinical trials segment being a significant portion. IXICO is positioned to capture a share of this market through its specialized services.
Upturn SWOT Analysis
Strengths
- Expertise in neuroimaging for neurological disorders
- Proprietary data analytics capabilities
- Strong relationships with pharmaceutical companies
- Established ixCONNECT platform
Weaknesses
- Relatively small size compared to larger CROs
- Dependence on clinical trial activity
- Limited geographic diversification
- Risk of technological obsolescence
Opportunities
- Expanding into new neurological indications
- Developing new imaging biomarkers
- Forming strategic partnerships with other companies
- Leveraging AI and machine learning for data analysis
- Increased clinical trial activity
Threats
- Competition from larger CROs
- Changes in regulatory requirements
- Patent expirations
- Economic downturn affecting R&D spending
Competitors and Market Share
Key Competitors
- Bioclinica
- Medpace (MEDP)
- Clario
Competitive Landscape
IXICO is a specialist player in neuroimaging. They have a competitive advantage in neurology but needs to compete with larger CROs with broader service offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on their financial statements. Information not accessible through public API.
Future Projections: Future projections depend on analyst estimates. Information not accessible through public API.
Recent Initiatives: Focus on ixCONNECTu00ae platform expansion, new biomarker development, and strategic partnerships.
Summary
IXICO (IXQUF) is a specialized neuroimaging services provider with strengths in neurological disease expertise and a proprietary platform, ixCONNECTu00ae. While smaller than major CROs, its targeted focus and biomarker development offer growth potential. They need to mitigate competition and adapt to evolving regulatory and technological landscapes. Strategic partnerships and technological advancements will drive IXICOu2019s future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Competitor Analysis
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data is based on estimations and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IXQUF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-07 | CEO, CFO, COO & Director Mr. Noah Aptekar | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.ixacq.com |
Full time employees - | Website https://www.ixacq.com | ||
IX Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on companies in technology, media and telecommunications, and information and communication technology industries, as well as companies operating in telecommunications infrastructure, internet and technology, and digital services sectors in Europe and other markets. The company was incorporated in 2021 and is based in London, United Kingdom. IX Acquisition Corp. is a subsidiary of IX Acquisition Sponsor LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.